Pharma.ai: Accelerating Pharmaceutical Research with Generative AI

pharma.ai is a powerful, end-to-end generative AI platform developed by Insilico Medicine, designed to revolutionize pharmaceutical research by integrating advanced AI technologies across drug discovery, target identification, and clinical trial prediction. It combines multiple specialized tools—PandaOmics for omics-driven target and biomarker discovery, Chemistry42 for small molecule design and optimization, Generative Biologics for biologics engineering, inClinico for clinical trial success forecasting, and more—into a unified, secure, and customizable solution. With capabilities in de novo drug design, ADMET profiling, retrosynthesis planning, kinome activity prediction, and AI-augmented trial simulation, pharma.ai empowers researchers with data-driven insights and automation. Its on-premise deployment options, including the secure PandaOmics Box with a Local LLM and ISAP-powered confidential computing, ensure privacy and compliance for sensitive research data. The platform supports seamless integration with external tools and offers Open API access for tailored workflows, making it ideal for complex, high-stakes research environments.

Key Features:

• Generative AI for Drug Discovery: Enables de novo design, hit optimization, scaffold hopping, and R-groups search in small molecule development.
• ADMET Profiling: Predicts and optimizes physicochemical and ADMET properties for early-stage drug candidates.
• Alchemistry: Provides accurate relative binding free energy estimation for improved molecular affinity predictions.
• Retrosynthesis Planning: Recommends synthetic routes using a library of 300,000 commercially available building blocks.
• Golden Cubes Engine: Predicts kinome activity and identifies off-target effects using multi-dimensional Self-Organizing Maps.
• inClinico Platform: Offers multimodal forecasting of clinical trial probability of success with real-time risk assessment and trial design simulation.
• Comprehensive Knowledge Base: Integrates 5 million omics samples, 30 million publications, 3 million grants, 3.8 million patents, 342,000 clinical trials, and 13,000 drugs.
• Customizable Workflows: Supports hit identification, hit-to-lead, and lead optimization pipelines.
• On-Premise Deployment: PandaOmics Box offers secure, private, and compliant data handling with no external transmission.
• Insilico Secure Application Platform (ISAP): Implements chip-level confidential computing and multi-layered security for sensitive research.
• Local Large Language Model (LLM): Powers secure, private, and high-performance AI interactions directly on user systems.
• ChatPandaGPT: Enables natural, conversational querying of the knowledge graph for intuitive data exploration.
• Open API Access: Allows integration with external tools like QSAR models, MD simulators, and in-house databases.
• Automated Research Workflows: Streamlines data analysis and reduces manual effort across the drug development lifecycle.
• Publication-Ready Outputs: Includes a Paper Drafting Tool and automatic generation of Comprehensive Gene-Disease Reports.
• Flexible Business Models: Offers standalone software access or bundled technology and service packages for tailored AI partnerships.

Pricing: pharma.ai provides flexible pricing through standalone access and integrated service packages, with a trial model available for evaluation.

Conclusion: pharma.ai stands as a transformative force in pharmaceutical R&D, combining cutting-edge generative AI with secure, scalable infrastructure to accelerate discovery, de-risk development, and empower researchers with intelligent, actionable insights.